T-regulatory cells are relatively deficient in squamous carcinomas undergoing regression in mice immunized with a squamous carcinoma vaccine enriched for immunotherapeutic cells

Cancer Gene Therapy

Volumn 14, Issue 6, 2007, Pages 573-582

  Chopra, A ^a   O Sullivan, I ^a   Carr, J ^a   Kim, T S ^b   Cohen, E P ^a,c  

^a UNIVERSITY OF ILLINOIS   (United States)

^b Korea University   (South Korea)

^c Department of Microbiology and Immunology ^*  (United States)

Author keywords

DNA based vaccine; Immunotherapy; Mice; Squamous carcinoma; T regulatory cells

Indexed keywords

CANCER VACCINE; CD4 ANTIGEN; CD8 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DNA VACCINE; INTERLEUKIN 2 RECEPTOR ALPHA; L SELECTIN; TRANSCRIPTION FACTOR FOXP3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER IMMUNIZATION; CANCER REGRESSION; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; FEMALE; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE SUBPOPULATION;

MUS;

EID: 34249083136     PISSN: 09291903     EISSN: 14765500     Source Type: Journal    
DOI: 10.1038/sj.cgt.7701040     Document Type: Article

References (51)

1. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006; 16: 3-15.
2. Meissner M, Reichert TE, Kunkel M, Gooding W, Whiteside TL, Ferrone S et al. Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res 2005; 11: 2552-2560.
3. Whiteside TL. Immunobiology of head and neck cancer. Cancer Metastasis Rev 2005; 24: 95-105.
4. Ferris RL. Progress in head and neck cancer immunotherapy: can tolerance and immune suppression be reversed? ORL J Otorhinolaryngol Relat Spec 2004; 66: 332-340.
5. Bas M, Bier H, Schirlau K, Friebe-Hoffmann U, Scheckenbach K, Balz V et al. Gamma-delta T-cells in patients with squamous cell carcinoma of the head and neck. Oral Oncol 2006; 42: 691-697.
6. Di Pucchio T, Pilla L, Capone I, Ferrantini M, Montefiore E, Urbani F et al. Immunization of stage IV melanoma patients with Melan-A/MART-1 and gp100 peptides plus IFN-alpha results in the activation of specific CD8(+) T cells and monocyte/dendritic cell precursors. Cancer Res 2006; 66: 4943-4951.
7. Slingluff Jr CL, Engelhard VH, Ferrone S. Peptide and dendritic cell vaccines. Clin Cancer Res 2006; 12: 2342-2345.
8. Lee WC, Wang HC, Hung CF, Huang PF, Lia CR, Chen MF. Vaccination of advanced hepatocellular carcinoma patients with tumor lysate-pulsed dendritic cells: a clinical trial. J Immunother 2005; 28: 496-504.
9. Hus I, Rolinski J, Tabarkiewicz J, Wojas K, Bojarska-Junak A, Greiner J et al. Allogeneic dendritic cells pulsed with tumor lysates or apoptotic bodies as immunotherapy for patients with early-stage B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 1621-1627.
10. Rosell R, Cecere F, Cognetti F, Cuello M, Sanchez JM, Taron M et al. Future directions in the second-line treatment of non-small cell lung cancer. Semin Oncol 2006; 33: S45-S51.
11. Mu LJ, Kyte JA, Kvalheim G, Aamdal S, Dueland S, Hauser M et al. Immunotherapy with allotumour mRNA-transfected dendritic cells in androgen-resistant prostate cancer patients. Br J Cancer 2005; 93: 749-756.
12. Ribas A. Genetically modified dendritic cells for cancer immunotherapy. Curr Gene Ther 2005; 5: 619-628.
13. Cuadros C, Dominguez AL, Lollini PL, Croft M, Mittler RS, Borgstrom P et al. Vaccination with dendritic cells pulsed with apoptotic tumors in combination with anti-OX40 and anti-4-1BB monoclonal antibodies induces T cell-mediated protective mmunity in Her-2/neu transgenic mice. Int J Cancer 2005; 116: 934-943.
14. Dunn G, Oliver KM, Loke D, Stafford ND, Greenman J. Dendritic cells and HNSCC: a potential treatment option? Oncol Rep 2005; 13: 3-10.
15. Wang HH, Mao CY, Teng LS, Cao J. Recent advances in heat shock protein-based cancer vaccines. Hepatobiliary Pancreat Dis Int 2006; 5: 22-27.
16. Zeng Y, Graner MW, Katsanis E. Chaperone-rich cell lysates, immune activation and tumor vaccination. Cancer Immunol Immunother 2006; 55: 329-338.
17. O-Sullivan I, Kim TS, Chopra A, Cohen EP. Therapeutic properties of DNA-based fibroblast and dendritic cell vaccines in mice with squamous carcinoma. Anticancer Res 2006; 26: 873-884.
18. Chopra A, Kim TS, O-Sullivan I, Martinez D, Cohen EP. Treatment of squamous carcinoma in mice with a vaccine enriched for cells that induce immunity to squamous carcinoma - a newvaccination strategy. Int J Cancer 2006; 119: 339-348.
19. Kim TS, Cohen EP. Immunity to breast cancer in mice immunized with fibroblasts transfected with a cDNA expression library derived from small numbers of breast cancer cells. Cancer Gene Ther 2005; 12: 890-899.
20. Whiteside TL, Gambotto A, Albers A, Stanson J, Cohen EP. Human tumor-derived genomic DNA transduced into a recipient cell induces tumor-specific immune responses ex vivo. Proc Natl Acad Sci USA 2002; 99: 9415-9420.
21. Sondak VK, Sabel MS, Mule JJ. Allogeneic and autologous melanoma vaccines: where have we been and where are we going? Clin Cancer Res 2006; 12: 2337s-2341s.
22. Errington F, Bateman A, Kottke T, Thompson J, Harrington K, Merrick A et al. Allogeneic tumor cells expressing fusogenic membrane glycoproteins as a platform for clinical cancer immunotherapy. Clin Cancer Res 2006; 12: 1333-1341.
23. Cheong SC, Blangenois I, Franssen JD, Servais C, Phan V, Trakatelli M et al. Generation of cell hybrids via a fusogenic cell line. J Gene Med 2006; 8: 919-928.
24. Palmowski MJ, Gileadi U, Salio M, Gallimore A, Millrain M, James E et al. Role of immunoproteasomes in cross-presentation. J Immunol 2006; 177: 983-990.
25. Donohue KB, Grant JM, Tewalt EF, Palmer DC, Theoret MR, Restifo NP et al. Cross-priming utilizes antigen not available to the direct presentation pathway. Immunology 2006; 119: 63-73.
26. Wigler M, Pellicer A, Silverstein S, Axel R, Urlaub G, Chasin L. DNA-mediated transfer of the adenine phosphoribosyl transferase locus into mammalian cells. Proc Natl Acad Sci USA 1979; 76: 1373-1376.
27. Sakaguchi S, Fukuma K, Kuribiashi K, Masuda T. Organ specific autoimmune disease induced in mice by elimination of T cell subsets. I. Evidence for the active participation of T cells in natural self-tolerance: deficit of a subset as possible cause of autoimmunity. J Exp Med 1985; 161: 72-87.
28. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M. Immunologic self tolerance maintained by activated T cells expressing IL-2 receptor a chain (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J Immunol 1995; 155: 1151-1164.
29. Berendt MJ, North RJ. T cell mediated suppression of anti tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med 1980; 151: 69-80.
30. North RJ. Down regulation of the anti tumor immune response. Adv Cancer Res 1985; 45: 1-43.
31. Mukherji B, Wilhelm SA, Guha A, Ergin MT. Regulation of cellular immune response against autologous human melanoma. I. Evidence for cell mediated suppression of in vitro cytotoxic immune response. J Immunol 1986; 136: 1888-1892.
32. Terabe M, Berzofsky JA. Immunoregulatory T cells in tumor immunity. Curr Opin Immunol 2004; 16: 157-162.
33. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor FoxP3. Science 2003; 299: 1057-1061.
34. Fontenot JD, Rasmussen JP, Williams LM, Dooley JL, Farr AG, Rudensky AV. Regulatory T cell-lineage specification by the forkhead transcription factor FoxP3. Immunity 2005; 22: 329-341.
35. Kim TS, Jung MY, Cho D, Cohen EP. Prolongation of the survival of breast cancer-bearing mice immunized with GM-CSF-secreting syngeneic/allogeneic fibroblasts transfected with a cDNA expression library from breast cancer cells. Vaccine 2006; 24: 6564-6573.
36. Wang W, Epler J, Salazar LG, Riddell SR. Recognition of breast cancer cells by CD8+ cytotoxic T-cell clones specific for NY-BR-1. Cancer Res 2006; 66: 6826-6833.
37. Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E et al. American Cancer Society. Cancer Statistics, 2004. CA Cancer J Clin 2004; 54: 8-29.
38. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Eng J Med 2001; 345: 1890-1900.
39. Murphy GP, Lawrence W, Lenhhartd RE. Am Cancer Soc. Textbook of Clinical Oncology. 2nd edn. American Cancer Society: Atlanta, 1995.
40. Colnot DR, Quak JJ, Roos JC, de Bree R, Wilhelm AJ, Snow GB et al. Radioimmunotherapy in patients with head and neck squamous cell carcinoma: initial experience. Head Neck 2001; 23: 559-565.
41. Kuriakose MA, Chen FA, Egilmez NK, Jong YS, Mathiowitz E, DeLacure MD et al. Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model. Head Neck 2000; 22: 57-63.
42. Cortesina G, De Stefani A, Sacchi M, Rosso S, Galeazzi E. Immunomodulation therapy for squamous cell carcinoma of the head and neck. Head Neck 1993; 15: 266-270.
43. Kim TS, Chopra A, O-Sullivan IS, Cohen EP. Enhanced immunity to breast cancer in mice immunized with fibroblasts transfected with a complementary DNA expression library from breast cancer cells: Enrichment of the vaccine for immunotherapeutic cells. J Immunother 2006; 29: 261-273.
44. Chopra A, Kim TS, O-Sullivan I, Martinez D, Cohen EP. Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based cell vaccine. Int J Cancer 2006; 118: 2888-2898.
45. Shimizu J, Yamazaki S, Sakaguchi S. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999; 163: 5211-5218.
46. Gallimore A, Sakaguchii S. Regulation of tumor immunity by CD25+ T cells. Immunology 2002; 107: 5-9.
47. Wei-Zen W, Morris GP, Kong Yi-chi M. Anti tumor immunity and autoimmunity: a balancing act of regulatory T cells. Cancer Immunol Immunother 2004; 53: 73-78.
48. Tanaka H, Tanaka J, Kjaergaard J, Shu S. Depletion of CD4+CD25+ regulatory cells augments the generation of specific T cells in tumor-draining lymph nodes. J Immunother 2002; 25: 207-217.
49. Antony PA, Piccrillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR et al. CD8+ T cell immunity against a tumor/self antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005; 1744 2591-2601.
50. Zhou G, Drake CG, Levitsky HI. Amplification of tumor-specific regulatory T cells following therapeutic cancer vaccines. Blood 2006; 107: 628-636.
51. Hiura T, Kagamu H, Miura S, Ishida A, Tanaka H, Tanaka J et al. Both regulatory T cells and anti tumor effector cells are primed in the same draining lymph nodes during tumor progression. J Immunol 2005; 175: 5058-5066.